Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniae
2022-08-30
999+
学术论著
上一篇：Efficacy Safety and Pharmacokinetics of Recombinant Human Coagulation Factor VIII (Omfiloctocog alfa) in Previously Treated Children with Severe Hemophilia A.
下一篇：Immunogenicity correlation in cynomolgus monkeys between Luminex‐d total IgG immunoassay and pseudovirion‐ d neutralization assay for a 14‐valent recombinant human papillomavirus vaccine
最新资讯
-
Efficacy Safety and Pharmacokinetics of Recombinant Human Coagulation Factor VIII (Omfiloctocog alfa) in Previously Treated Children with Severe Hemophilia A.
2022-08-30 -
Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and Streptococcus pneumoniae
2022-08-30 -
Immunogenicity correlation in cynomolgus monkeys between Luminex‐d total IgG immunoassay and pseudovirion‐ d neutralization assay for a 14‐valent recombinant human papillomavirus vaccine
2022-08-30 -
Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters
2022-08-30